Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CTBP2 | P56545 | 3/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL8994440 | 1.00 | L3MBTL1 (0.41) | L3MBTL1TDP1SMN1; SMN2LMNAMEN1 | |
| Toluene SCHEMBL1079482 | 1.00 | L3MBTL1 (0.41) | L3MBTL1TDP1SMN1; SMN2LMNAMEN1 | |
| Toluene SCHEMBL1159746 | 1.00 | L3MBTL1 (0.41) | L3MBTL1TDP1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL7789892 | 0.90 | POLB (0.42) | L3MBTL1TDP1LMNAMEN1KMT2A | |
| SCHEMBL2332010 | 0.85 | SLC22A12 (0.44) | TDP1SMN1; SMN2LMNAMEN1KMT2A | |
| Toluene SCHEMBL1245378 | 0.83 | L3MBTL1 (0.45) | L3MBTL1TDP1SMN1; SMN2LMNAMEN1 | |
| Toluene SCHEMBL7782221 | 0.83 | L3MBTL1 (0.45) | L3MBTL1TDP1SMN1; SMN2LMNAMEN1 | |
| Toluene SCHEMBL1245372 | 0.83 | L3MBTL1 (0.45) | L3MBTL1TDP1SMN1; SMN2LMNAMEN1 | |
| Toluene SCHEMBL1078154 | 0.83 | L3MBTL1 (0.45) | L3MBTL1TDP1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL210161 | 0.81 | PKM (0.42) | L3MBTL1LMNAMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850334-B2 | Immobilised biological entities | CARMEDA AB (SE) | 2023-12-26 | — | — | US | disclosed |
| US-20210379253-A1 | IMMOBILISED BIOLOGICAL ENTITIES | CARMEDA AB (SE) | 2021-12-09 | — | — | US | disclosed |
| EP-3860670-A1 | IMMOBILISED BIOLOGICAL ENTITIES | Carmeda AB (SE) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020070258-A1 | IMMOBILISED BIOLOGICAL ENTITIES | CARMEDA AB (SE) | 2020-04-09 | — | — | WO | disclosed |
| EP-3292125-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2019-09-04 | — | — | EP | disclosed |
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2019-01-22 | — | — | US | disclosed |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2018-04-05 | — | — | US | disclosed |
| EP-3292125-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177862-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2016-11-10 | — | — | WO | disclosed |
| EP-3091018-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-5625043-A | ANTITUMOR CHEMOTHERAPY | Priebe, Waldemar | 1997-04-29 | — | — | US | disclosed |
| WO-1994020114-A1 | ANTHRACYCLINES WITH UNUSUALLY HIGH ACTIVITY AGAINST CELLS RESISTANT TO DOXORUBICIN AND ITS ANALOGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, PEPD, LCT | L3MBTL1 1342/4885TDP1 3537/4885SMN1; SMN2 3965/4885 |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | NQO1, PEPD, LCT | L3MBTL1 1342/4885TDP1 3537/4885SMN1; SMN2 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.